Pharma assns demand setting up of NIPER in silk city

Berhampur:  Several pharmacist associations staged a rally on Monday and submitted a memorandum to Prime Minister Narendra Modi and chief minister Mohan Charan Majhi through the revenue divisional commissioner (south) demanding establishment of a National Institute of Pharmaceutical Education and Research (NIPER) in Berhampur.

Members of the South Odisha Pharmacists Association (SOPA), Ganjam-Phulbani Druggists’ and Chemists Association (GPDCA), and several pharmacy students from different institutes here took part in the rally. The rally started from MKCG Medical College and Hospital and went until the RDC’s residence.

P Satyanarayana, president of GPDCA, said pharmacy education started in the state in 1979. “There are five pharmacy institutes in the city that are imparting BPharm and MPharm courses. Students who pass out are doing jobs in various companies. If NIPER is established in Berhampur, students from Odisha and neighbouring states would benefit,” he said.

Bijay Kumar Swain, president of SOPA, said Berhampur has all the potential facilities for the establishment of NIPER. “Its establishment is important as the state govt has planned to set up a pharma cluster in Gopalpur by inviting pharmaceutical companies. Several pharma companies have also shown their keenness to set up units in Gopalpur,” he said.

Earlier, several social activists and all BJP MLAs of Ganjam district submitted memorandums to Majhi demanding the establishment of NIPER at Berhampur, while local MP Pradeep Kumar Panigrahy wrote a letter to the PM and CM in this regard.

NIPERs are now functioning at Mohali, Ahmedabad, Hajipur, Hyderabad, Kolkata, Guwahati and Rae Bareli.

Related Posts

Rajasthan Bans 7 Sub-Standard Medicines

Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality”. Prioritising…

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

Rajasthan Bans 7 Sub-Standard Medicines

Rajasthan Bans 7 Sub-Standard Medicines

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23